Latest From Oncorus Inc.
Transgene's CEO discusses its immunotherapy pipeline, coming catalysts, and why the French biotech may soon be swept up by growing interest in oncolytic viruses.
PsiOxus Therapeutics' CEO tells Scrip it will seek the fresh funding next year to progress its pipeline which aims to treat solid tumors through systemic delivery of oncolytic viruses.
This week's roundup includes CEO appointments by CRISPR Therapeutics and KSQ Therapeutics, in addition to various other board and high-level appointments by Oncorus, Cellectis, BiOasis, Avillion and Revolution Medicines.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Oncorus Inc.
- Senior Management
Mitchell H Finer, PhD, CEO
Thomas W Chalberg, PhD, COO
Cyrus D Mozayeni, MD, Pres. & CBO
Christophe Queva, PhD, CSO & SVP, Research
Eric M Sullivan, SVP, Finance & Ops.
- Contact Info
Phone: (857) 320-6402
450 Kendall St., 4th Fl.
Cambridge, MA 02142
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.